Literature DB >> 24025971

CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells.

Young H Choi1, Marie D Burdick, Brett A Strieter, Borna Mehrad, Robert M Strieter.   

Abstract

UNLABELLED: Chemokines have been implicated as key contributors of non-small cell lung cancer (NSCLC) metastasis. However, the role of CXCR7, a recently discovered receptor for CXCL12 ligand, in the pathogenesis of NSCLC is unknown. To define the relative contribution of chemokine receptors to migration and metastasis, we generated human lung A549 and H157 cell lines with stable knockdown of CXCR4, CXCR7, or both. Cancer cells exhibited chemotaxis to CXCL12 that was enhanced under hypoxic conditions, associated with a parallel induction of CXCR4, but not CXCR7. Interestingly, neither knockdown cell line differed in the rate of proliferation, apoptosis, or cell adherence; however, in both cell lines, CXCL12-induced migration was abolished when CXCR4 signaling was abrogated. In contrast, inhibition of CXCR7 signaling did not alter cellular migration to CXCL12. In an in vivo heterotropic xenograft model using A549 cells, expression of CXCR4, but not CXCR7, on cancer cells was necessary for the development of metastases. In addition, cancer cells knocked down for CXCR4 (or both CXCR4 and CXCR7) produced larger and more vascular tumors as compared with wild-type or CXCR7 knockdown tumors, an effect that was attributable to cancer cell-derived CXCR4 out competing endothelial cells for available CXCL12 in the tumor microenvironment. These results indicate that CXCR4, not CXCR7, expression engages CXCL12 to mediate NSCLC metastatic behavior. IMPLICATIONS: Targeting CXCR4-mediated migration and metastasis may be a viable therapeutic option in NSCLC. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24025971      PMCID: PMC4262747          DOI: 10.1158/1541-7786.MCR-12-0334

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  39 in total

1.  Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.

Authors:  Russell S Taichman; Carlton Cooper; Evan T Keller; Kenneth J Pienta; Norton S Taichman; Laurie K McCauley
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

2.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.

Authors:  Roderick J Phillips; Marie D Burdick; Marin Lutz; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  Am J Respir Crit Care Med       Date:  2003-03-05       Impact factor: 21.405

3.  A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma.

Authors:  H Geminder; O Sagi-Assif; L Goldberg; T Meshel; G Rechavi; I P Witz; A Ben-Baruch
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

4.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.

Authors:  Chris J Scotton; Julia L Wilson; Kate Scott; Gordon Stamp; George D Wilbanks; Simon Fricker; Gary Bridger; Frances R Balkwill
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

5.  The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity.

Authors:  C L Addison; T O Daniel; M D Burdick; H Liu; J E Ehlert; Y Y Xue; L Buechi; A Walz; A Richmond; R M Strieter
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

6.  Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice.

Authors:  D A Arenberg; S L Kunkel; P J Polverini; M Glass; M D Burdick; R M Strieter
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

7.  Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1.

Authors:  Ombretta Salvucci; Lei Yao; Sabrina Villalba; Agatha Sajewicz; Stefania Pittaluga; Giovanna Tosato
Journal:  Blood       Date:  2002-04-15       Impact factor: 22.113

8.  The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature.

Authors:  Yoshitsugu Takabatake; Tatsuki Sugiyama; Hiroshi Kohara; Taiji Matsusaka; Hidetake Kurihara; Pandelakis A Koni; Yasuyuki Nagasawa; Takayuki Hamano; Isao Matsui; Noritaka Kawada; Enyu Imai; Takashi Nagasawa; Hiromi Rakugi; Yoshitaka Isaka
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

9.  CXCR4/CXCL12 expression and signalling in kidney cancer.

Authors:  A J Schrader; O Lechner; M Templin; K E J Dittmar; S Machtens; M Mengel; M Probst-Kepper; A Franzke; T Wollensak; P Gatzlaff; J Atzpodien; J Buer; J Lauber
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

10.  Regulation of the chemokine receptor CXCR4 by hypoxia.

Authors:  Tiziana Schioppa; Badarch Uranchimeg; Alessandra Saccani; Subhra K Biswas; Andrea Doni; Annamaria Rapisarda; Sergio Bernasconi; Simona Saccani; Manuela Nebuloni; Luca Vago; Alberto Mantovani; Giovanni Melillo; Antonio Sica
Journal:  J Exp Med       Date:  2003-11-03       Impact factor: 14.307

View more
  32 in total

1.  Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia.

Authors:  Aline C Oliveira; Chunhua Fu; Yuanqing Lu; Mason A Williams; Liya Pi; Mark L Brantly; Corey E Ventetuolo; Mohan K Raizada; Borna Mehrad; Edward W Scott; Andrew J Bryant
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-07-31       Impact factor: 5.464

Review 2.  The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.

Authors:  Sharilyn Almodovar
Journal:  Viral Immunol       Date:  2014-05-05       Impact factor: 2.257

3.  Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma.

Authors:  Raheleh Roudi; Zahra Madjd; Marzieh Ebrahimi; Ali Najafi; Alireza Korourian; Ahmad Shariftabrizi; Ali Samadikuchaksaraei
Journal:  Tumour Biol       Date:  2016-04-05

Review 4.  Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Authors:  Weiqiang Zhou; Shanchun Guo; Mingli Liu; Matthew E Burow; Guangdi Wang
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

5.  Grb2-associated binder-2 gene promotes migration of non-small cell lung cancer cells via Akt signaling pathway.

Authors:  Li Jun Xu; Yu Chang Wang; Hong Wen Lan; Jun Li; Tian Xia
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

6.  Internal tandem duplication mutations in FLT3 gene augment chemotaxis to Cxcl12 protein by blocking the down-regulation of the Rho-associated kinase via the Cxcl12/Cxcr4 signaling axis.

Authors:  Chie Onishi; Chie Onish; Satomi Mori-Kimachi; Tomohiro Hirade; Mariko Abe; Takeshi Taketani; Junji Suzumiya; Toshitsugu Sugimoto; Seiji Yamaguchi; Reuben Kapur; Seiji Fukuda
Journal:  J Biol Chem       Date:  2014-09-18       Impact factor: 5.157

7.  Targeting CXC motif chemokine receptor 4 inhibits the proliferation, migration and angiogenesis of lung cancer cells.

Authors:  Wei He; Tong Yang; Xin-Hua Gong; Ru-Zhai Qin; Xiao-Dong Zhang; Wen-Dan Liu
Journal:  Oncol Lett       Date:  2018-07-04       Impact factor: 2.967

8.  NADPH oxidase 1-dependent ROS is crucial for TLR4 signaling to promote tumor metastasis of non-small cell lung cancer.

Authors:  Xiyu Liu; Changyan Pei; Song Yan; Guifeng Liu; Gang Liu; Wenqing Chen; Youbin Cui; Yahui Liu
Journal:  Tumour Biol       Date:  2015-01-16

9.  Interactions between CXCR4 and CXCL12 promote cell migration and invasion of canine hemangiosarcoma.

Authors:  K S Im; A J Graef; M Breen; K Lindblad-Toh; J F Modiano; J-H Kim
Journal:  Vet Comp Oncol       Date:  2015-09-03       Impact factor: 2.613

10.  CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer.

Authors:  Y-C Wu; S-J Tang; G-H Sun; K-H Sun
Journal:  Oncogene       Date:  2015-07-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.